Gross CP, 1998, IJID, 3, 54
Jenner E. An Inquiry into the Causes and Effects of the Variolae Vaccinae: A Disease Discovered in Some of the Western Counties of England, Particularly Gloucestershire, and Known by the Name of the Cow Pox. London: Sampson Low; 1798, 1-2
Jenner E, 1809, Med Chir Trans, 1, 271, 10.1177/095952870900100120
10.1017/S0025727300030714
Calmette A, 1931, Proc R Soc Med, 24, 1481
Mantoux C, 1910, Presse Med, 18, 10
10.1016/j.apnr.2004.09.009
10.1016/j.vaccine.2008.03.095
Dacso CC, Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition
Salisbury DM, 1996, Department of Health, London
10.1111/j.1708-8305.2009.00351.x
10.1002/14651858.CD000100.pub3
10.1016/j.vaccine.2009.01.043
10.1016/S0140-6736(89)92533-6
10.1001/jama.1985.03360220069031
10.1001/jama.1995.03520470043027
10.1016/S0264-410X(01)00468-6
10.1016/S0140-6736(85)92367-0
10.1016/j.vaccine.2004.09.027
10.1016/j.vaccine.2006.01.051
World Health Organization, 2010, Wkly Epi demiol Rec, 85, 309
10.1016/j.vaccine.2011.12.069
10.1016/S0140-6736(84)90873-0
10.1016/j.vaccine.2012.09.062
10.1016/j.vaccine.2008.10.077
10.1016/j.vaccine.2007.06.066
10.1016/j.vaccine.2013.09.074
10.1016/j.vaccine.2014.03.024
10.1371/journal.pone.0001993
10.1016/j.vaccine.2009.02.049
Hickling J, 2013, PATH report
10.1016/S0264-410X(97)00293-4
10.1016/S1473-3099(11)70190-6
10.1016/S0264-410X(02)00028-2
10.1016/j.vaccine.2010.09.024
10.1517/17425247.2014.885947
10.1056/NEJM199409223311206
Tuft L, 1931, J Immunol, 21, 85, 10.4049/jimmunol.21.2.85
10.1016/j.vaccine.2007.10.020
10.1016/j.vaccine.2009.10.033
10.1016/j.vaccine.2014.07.095
10.3748/wjg.v20.i30.10383
10.1111/j.1365-2893.2010.01354.x
10.1016/j.vaccine.2011.11.020
10.1016/j.vaccine.2006.08.026
10.1093/infdis/136.Supplement_3.S466
10.1093/infdis/140.2.234b
10.1016/0140-6736(91)90480-D
10.1016/0264-410X(92)90039-M
10.1016/j.vaccine.2010.06.062
10.1007/s00232-010-9283-0
10.1016/j.addr.2003.10.023
10.1016/j.vaccine.2009.03.073
10.1016/j.jconrel.2009.06.033
Ten Dam HG, 1970, Bull WHO, 43, 707
10.1016/j.vaccine.2013.05.104
Dimache G1, 1990, Arch Roum Pathol Exp Microbiol, 49, 51
10.1016/S0092-1157(83)80014-6
Dimache G, 1982, Arch Roum Pathol Exp Microbiol, 41, 259
Dimache G, 1976, Arch Roum Pathol Exp Microbiol, 36, 227
10.1001/jama.1982.03320330034022
10.1016/S0140-6736(14)60524-9
Meyer Jr, 1964, Bull World Health Organ, 30, 783
10.1007/978-3-642-00477-3_7
10.1016/j.vaccine.2014.01.076
10.1007/s12325-011-0042-0
10.1007/s12325-011-0090-5
10.1109/JMEMS.2003.820293
Rebeiz GM, 2004, RF MEMS: Theory, Design, and Technology
Nadim Maluf, 2004, An Introduction to Microelectromechanical Systems Engineering
10.1016/j.vaccine.2012.08.014
10.1016/j.vaccine.2009.05.066
10.1016/j.vaccine.2011.07.111
Investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoints in MAGRIT, a phase III non-small cell lung cancer clinical trial. Issued: Thursday 20 March 2014, London UK; Retrieved June 23, 2014: http://www.gsk.com/media/press-releases/2014/investigational-MAGE-A3-antigen-specific-cancer-immunotherapeutic-does-not-meet-first-co-primary-endpoints-in-MAGRIT.html
10.1126/science.342.6165.1432
